KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Current Assets (2016 - 2025)

Biogen (BIIB) has 17 years of Current Assets data on record, last reported at $9.0 billion in Q4 2025.

  • For Q4 2025, Current Assets rose 20.35% year-over-year to $9.0 billion; the TTM value through Dec 2025 reached $9.0 billion, up 20.35%, while the annual FY2025 figure was $9.0 billion, 20.35% up from the prior year.
  • Current Assets reached $9.0 billion in Q4 2025 per BIIB's latest filing, roughly flat from $8.9 billion in the prior quarter.
  • Across five years, Current Assets topped out at $10.4 billion in Q2 2023 and bottomed at $6.7 billion in Q1 2021.
  • Average Current Assets over 5 years is $8.2 billion, with a median of $7.9 billion recorded in 2021.
  • Peak YoY movement for Current Assets: surged 36.35% in 2022, then crashed 31.86% in 2024.
  • A 5-year view of Current Assets shows it stood at $7.9 billion in 2021, then grew by 24.63% to $9.8 billion in 2022, then fell by 29.94% to $6.9 billion in 2023, then grew by 8.71% to $7.5 billion in 2024, then grew by 20.35% to $9.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $9.0 billion in Q4 2025, $8.9 billion in Q3 2025, and $8.0 billion in Q2 2025.